AUTHOR=Huang Zhijian , Yi Limu , Jin Liangzi , Chen Jian , Han Yuanyuan , Zhang Yan , Shi Libin 

TITLE=Systematic analysis of virus nucleic acid sensor DDX58 in malignant tumor

JOURNAL=Frontiers in Microbiology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1085086

DOI=10.3389/fmicb.2022.1085086

ISSN=1664-302X

ABSTRACT=<sec><title>Introduction</title><p>In December 2019, a novel epidemic of coronavirus pneumonia (COVID-19) was reported，and population-based studies had shown that cancer was a risk factor for death from COVID-19 infection. However, the molecular mechanism between COVID-19 and cancer remains indistinct. In this paper, we analyzed the nucleic acid sensor (<italic>DDX58</italic>) of SARS-CoV-2 virus, which is a significant gene related to virus infection. For purpose of clarifying the characteristics of <italic>DDX58</italic> expression in malignant tumors, this study began to systematically analyze the <italic>DDX58</italic> expression profile in the entire cancer type spectrum.</p></sec><sec><title>Methods</title><p>Using TCGA pan-cancer database and related data resources, we analyzed the expression, survival analysis, methylation expression, mutation status, microsatellite instability (MSI), immune related microenvironment, gene related network, function and drug sensitivity of <italic>DDX58</italic>.</p></sec><sec><title>Results</title><p>The expression level of <italic>DDX58</italic> mRNA in most cancers was higher than the expression level in normal tissues. Through TIMER algorithm mining, we found that <italic>DDX58</italic> expression was closely related to various levels of immune infiltration in pan-cancer. The promoter methylation level of <italic>DDX58</italic> was significantly increased in multiple cancers. In addition, abnormal expression of <italic>DDX58</italic> was related to MSI and TMB in multiple cancers, and the most common type of genomic mutation was “mutation.” In the protein–protein interaction (PPI) network, we found that type I interferon, phagocytosis, ubiquitinase, and tumor pathways were significantly enriched. Finally, according to the expression of <italic>DDX58</italic> indicated potential sensitive drugs such as Cediranib, VE−821, Itraconazole, JNJ−42756493, IWR−1, and Linsitinib.</p></sec><sec><title>Discussion</title><p>In conclusion, we had gained new insights into how <italic>DDX58</italic> might contribute to tumor development, and <italic>DDX58</italic> could be used as an immune-related biomarker and as a potential immunotherapeutic target for COVID-19 infected cancer patients.</p></sec>